NICE Endorses Natalizumab RRMS Treatment Expans...

By João L. Carapinha

January 9, 2026

NICE Expands Access to Natalizumab RRMS Treatment for Highly Active Cases The National Institute for Health and Care Excellence (NICE) has issued final draft ...
Novartis Drug Pricing Agreement
INFARMED Leadership Appointments: A New Era in Health Regulation and Expertise
Preparing for the EU Health Technology Assessment: Key Insights from the Upco...
Strategic Avalere Health Appointments Enhance Leadership in Navigating US Hea...
Advancing EU Health Technology Assessment: Key Priorities in the HTACG Draft ...
Biomanufacturing Excellence Act: Strengthening U.S. Biopharmaceutical Manufac...
Medicare Drug Price Negotiations: Major Savings for Seniors on Cancer and Chr...
Advancements in Continuous Glucose Monitoring for Type 2 Diabetes Management
NICE Endorses Obecabtagene Autoleucel Therapy for Adult Relapsed B-Cell Leuka...
Rethinking HEOR Market Access Integration: A Call for Early Engagement Before...
Patient-Reported Outcomes Trends in Clinical Trials: Insights from 2008-2023
Health Investment Returns: Harnessing Health as a Strategic Economic Asset